# A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention

> **NCT00291902** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 80 (—)

## Conditions studied

- Coronary Heart Disease

## Interventions

- **DRUG:** SB-681323

## Key facts

- **NCT ID:** NCT00291902
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 80 (—)
- **Last updated:** 2012-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00291902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00291902, "A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00291902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*